Skip to content

Effects of low-frequency magnetic fields on sleep and markers of Alzheimer's disease in humans

Effects of low-frequency magnetic fields on sleep and markers of Alzheimer's disease in humans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00029254
Enrollment
40
Registered
2022-06-15
Start date
2022-12-01
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Group 1: Sham exposure (during the entire 8hr sleep recording in the laboratory
one night/participant) Group 2: Magnetic field with lower flux density (in the range from 1 to 5µT
(during the entire 8hr sleep recording in the laboratory
one night/participant) Group 3: Magnetic field with higher flux density (in the range up to 30µT
one night/participant)

Sponsors

Bundesamt für Strahlenschutz
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: • Current physical and mental health • Postmenopausal women (last menstruation one year ago) • No or stable internal medication • Currently no sleep disorder according to the International Classification of Sleep Disorders (ICSD 3; American Academy of Sleep Medicine, AASM, 2014) • Regular sleep-wake cycle (sleep diary) • Right-handedness • Non-smoker

Exclusion criteria

Exclusion criteria: • Use of hypnotics • Excessive consumption of substances that affect the central nervous system (including caffeinated drinks, alcohol, drugs) • Working on night shift (22:00 to 06:00) • Electronic or electrically conductive implants • Piercings or non-removable metal body jewelry • scores above cut-off in the Montreal Cognitive Assessment (MoCa, Nasreddine et al., 2005) • scores above cut-off ??in screening questionnaires on sleep and health

Design outcomes

Primary

MeasureTime frame
The primary endpoints are the sleep macrostructure and the objective sleep efficiency, as well as the Alzheimer-associated biomarkers Aß40/42 and tau proteins. The sleep parameters are recorded every night in the sleep laboratory (one night per exposure condition), the biomarkers are determined by taking a blood sample before and after every sleep recording in the sleep laboratory.

Secondary

MeasureTime frame
The secondary endpoints are memory performance in the declarative and procedural memory test as well as the parameters for the subjective sleep quality derived from the evening-morning protocol and possible physical symptoms. These endpoints are also collected before and after each sleep recording in the sleep laboratory.

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026